Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory (R/R) mantle cell lymphoma (MCL): A CIBMTR subgroup analysis by prior treatment.
Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory (R/R) mantle cell lymphoma (MCL): A CIBMTR subgroup analysis by prior treatment. Kambhampati, S., Ahmed, N., Hamadani, M., Grover, N., Shadman, M., Locke, F. L., Gerson, J. M., Frank, M., Budde, L., Wang, M., Hu, Z., Nunes, A., Dalton, D., Kloos, I., Lee, D., Xu, H., Pasquini, M. C., Herrera, A. LIPPINCOTT WILLIAMS & WILKINS. 2023View details for Web of Science ID 001053772003451